2025-09-23 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the provided data, formatted for clarity and insight.

**Report on Hims & Hers Health Inc. (HIMS)**

Hims & Hers Health Inc. (HIMS) is a multi-specialty telehealth platform focused on providing personalized health and wellness experiences to consumers.

**1. Performance Relative to S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 225.86%
*   **VOO Cumulative Return:** 75.56%
*   **Absolute Divergence:** 142.1 (Range: Min -88.4, Max: 288.9)
*   **Relative Divergence:** 61.1

**Analysis:**

HIMS has significantly outperformed the S&P 500 (VOO) with a substantial cumulative return difference of 142.1%. The Relative Divergence of 61.1 indicates that HIMS's performance is above its historical average compared to the S&P 500. This suggests a period of strong outperformance, but it is essential to consider the context of this divergence within the broader market environment.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha   | Beta   | Cap(B) |
| ---------- | -------- | -------- | ------- | ------ | ------ |
| 2019-2021  | -46.0%  | 51.0%  | -84.0% | -0.0  | 1.5    |
| 2020-2022  | -15.0%  | 72.1%  | -17.0% | -0.0  | 1.4    |
| 2021-2023  | -51.0%  | 72.1%  | -69.0% | -0.1  | 2.0    |
| 2022-2024  | 127.0% | 78.4%  | 101.0% | -0.1  | 5.5    |
| 2023-2025  | 221.0% | 80.7%  | 162.0% | -0.1  | 13.1   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly across different periods, with substantial negative growth in earlier periods and very high growth in the most recent period (2023-2025). This indicates a potentially volatile growth trajectory.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, suggesting significant price volatility and risk.
*   **Alpha:** Alpha values are largely negative in the past, suggesting underperformance relative to a benchmark. However, the 2022-2024 and 2023-2025 periods show strong positive Alpha, indicating significant outperformance.
*   **Beta:** Beta values are close to zero or slightly negative, implying a low correlation with the overall market. This can be both a strength (during market downturns) and a weakness (during market rallies).
*   **Cap(B):** The market capitalization has increased significantly over the years, reflecting the company's growth.

**2. Recent Stock Price Movement**

*   **Current Price:** 57.82
*   **Previous Close:** 57.82
*   **Change:** -0.12
*   **5-day Moving Average:** 53.84
*   **20-day Moving Average:** 48.55
*   **60-day Moving Average:** 50.54

**Analysis:**

The stock price is currently slightly down. The 5-day moving average is above the 20-day and 60-day moving averages, which suggests a recent upward trend. However, the slight negative change compared to the previous close warrants caution.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.34 (Low Risk)
*   **RSI:** 75.27 (Overbought)
*   **PPO:** 2.48
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.33)
*   **20-day Relative Divergence Change:** 6.2 (Positive - Short-term Increase)
*   **Expected Return:** -8.1% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates a low level of market risk.
*   The RSI is in overbought territory, suggesting the stock may be due for a correction.
*   The positive change in relative divergence indicates a recent short-term increase in outperformance.
*   The negative expected return suggests that, based on current conditions, the stock is expected to underperform the S&P 500 over the long term.
*   Last-market change suggests a minor intraday fluctuation.

**4. Recent News & Significant Events**

*   **[2025-09-22] Hims & Hers Expands Care Ecosystem via Global and Digital Innovation:** Positive news indicating growth and expansion.
*   **[2025-09-19] Series of Insider Sales:** Multiple reports of insider sales, which could be interpreted negatively by the market.
*   **[2025-09-19] Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why:** Counteracts the insider sales with a positive spin on the stock.

**Analysis:**

The news is mixed. While the expansion of the care ecosystem is a positive signal, the significant insider selling raises concerns about management's confidence in the company's future performance. The StockStory article provides some counterbalance, but the insider sales remain a key factor to consider.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (2.92)
*   **Opinions:** 12
*   **Target Price (avg/high/low):** 47.42 / 85.00 / 25.00

**Analysis:**

The analyst consensus is "Hold," suggesting a neutral outlook. The average target price ($47.42) is below the current price, indicating potential downside risk. The wide range between the high and low target prices reflects uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2025-08-04 | 0.06 | 0.32 B$   |

**Analysis:**

*   The recent EPS and revenue figures indicate growth in both metrics.
*   The company has shown strong positive EPS figures in recent quarters (2025-05-05, 2025-08-04).
*   Revenue has consistently increased, reflecting growing sales.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | $0.54B    | 76.39%        |
| 2025-03-31 | $0.59B    | 73.50%        |
| 2024-12-31 | $0.48B    | 76.81%        |
| 2024-09-30 | $0.40B    | 79.16%        |
| 2024-06-30 | $0.32B    | 81.30%        |

| Quarter    | Equity    | ROE    |
| ---------- | --------- | ------ |
| 2025-06-30 | $0.56B    | 7.55%  |
| 2025-03-31 | $0.55B    | 9.01%  |
| 2024-12-31 | $0.48B    | 5.46%  |
| 2024-09-30 | $0.44B    | 17.18% |
| 2024-06-30 | $0.36B    | 3.67%  |

**Analysis:**

*   **Revenue:** Consistent growth in revenue over the quarters, indicating increasing sales and market penetration.
*   **Profit Margin:** High and relatively stable profit margins, suggesting strong pricing power and cost management.
*   **Equity:** Equity has increased over the quarters, reflecting a strengthening financial position.
*   **ROE:** Return on Equity (ROE) varies, with a peak in Q3 2024. It indicates the company's ability to generate profit from shareholders' investments.

**7. Overall Summary**

Hims & Hers Health Inc. (HIMS) exhibits a mixed outlook. The company has shown substantial outperformance relative to the S&P 500, driven by strong revenue and earnings growth. However, the high volatility (indicated by MDD), the recent insider sales, and the negative expected return suggest potential risks. The RSI is currently in overbought territory, indicating a possible short-term correction. Analyst opinions are neutral ("Hold") with an average target price below the current level.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. Investors should carefully consider their risk tolerance and investment horizon. While the company's growth prospects are attractive, the potential for a correction and the negative long-term expected return suggest the need for careful monitoring and potentially hedging strategies. Further research into the reasons behind the insider sales and a closer examination of the company's competitive landscape are recommended before making any investment decisions.

